Subscribe

Ortin Global Ltd. (ORTINGLOBE.NS)

INR15.31 -0.68 (-4.25%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address D. No: 1-8-305, Ground Floor 500020
Hyderabad, IN
CEO Sanka Murali Krishna Murthy
IPO 2024-08-26
ISIN INE749B01020

Explore sections of this company profile

Also trades on Bombay Stock Exchange · ORTINGLOBE.BO (INR) Bombay Stock Exchange · ORTINLAABS.BO (INR) National Stock Exchange of India · ORTINGLOBE.NS (INR)
Description

Ortin Global Ltd., established in 1986 and headquartered in Hyderabad, India, is an Indian enterprise specializing in the manufacturing and trading of pharmaceuticals, drugs, and their intermediates. The company, formerly known as Ortin Laboratories Limited until its name change in June 2024, offers an extensive portfolio of pharmaceutical formulations available as tablets, capsules, syrups, and dry powders. These products address a wide spectrum of therapeutic areas, including anti-diabetics, anti-allergics, cardiovascular conditions, sedatives, anti-helminthics, analgesics, antipyretics, various antibiotics (quinolones, penicillins, cephalosporins, macrolides), antifungals, chemotherapeutics, antacids, anti-ulcerants, anti-spasmodics, calcium and iron supplements, anti-arthritic drugs, protein supplements, enzymes, vitamins, as well as psychiatry, appetite stimulant, gynecological, and anti-retroviral medications. Beyond finished dosage forms, Ortin Global produces active pharmaceutical ingredient (API) intermediates for anti-retroviral, anti-diabetic, analgesic, antipyretic, antibiotic, antifungal, anti-ulcerant, and anti-malarial applications. Its manufacturing capabilities also extend to fine chemicals, Grignard products, and alkali metal compounds. The company provides a range of specialized services, including process development, characterization of processes and products, analytical research and development, and assay development. It also offers R&D for new formulation brands and diagnostic services, focusing on the creation of rapid flow kits, assays, and reagents. Additionally, Ortin Global secures long-term contracts for manufacturing intermediates and developing new APIs, functions as a merchant exporter of finished pharmaceutical formulations, and holds interests in real estate.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
INR15.31 -0.68 (-4.25%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
15.6K
Beta
0.48
Float Shares
5.57M
Free Float %
68.5%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-3.17% -9.41% +26.69% +5.70% +31.17% +21.99% +56.37% -21.60% -21.60% -21.60% -21.60%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
15.31
Quality scores
MOAT Score
0 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    -70.6% Q1'26: -24.1% (vs Q1'25)
  • EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +12.5% Q1'26: +95.1% (vs Q1'25)
  • FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +23.9% Q1'26: -2,254.1% (vs Q1'25)
  • EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    -717.6% Q1'26: -22.4% (vs Q1'25)
  • ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    -44.1% Q1'26: -1.9% (vs Q1'25)
  • Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +0.1% Q1'26: +15.5% (vs Q1'25)
  • Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    -1.39× Q1'26: -33.95× (vs Q1'25)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.48) × ERP
WACC = 93% × Ke + 7% × Kd (4.2%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
Current price: 15.31
Enterprise Value: Equity Value: Terminal Value: TV as % of EV:

Base values reflect the latest available data for this company and market conditions.

Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-06-12 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-06-11 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-06-10 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-06-09 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-06-08 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-06-05 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-06-04 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-06-03 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-06-02 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-06-01 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-29 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-27 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-26 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-25 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-19 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-18 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-15 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-14 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-13 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-12 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-11 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-08 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-07 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-06 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-05 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-04 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-30 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-29 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-28 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-27 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-24 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-23 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-17 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-16 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-7.76M
OE per share TTM
-0.96
Owner's Yield
-4.79%
Maintenance CapEx ratio
Maint CapEx / Avg PPE
1.9%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
Total invested
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-24.0K
Shares Outstanding
8.13M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Madhu Mala Solanki Company Secretary & Compliance Officer female
Prakruti Prashant Sawant Whole-Time Director female
Prashant Prakash Sawant Whole-Time Director male
Rahul Madanlal Wani Chief Financial Officer male
Sanka Murali Krishna Murthy MD & Director male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings reports

Stock splits